News | Prostate Cancer | October 27, 2016

Augmenix Announces Positive Three-year SpaceOAR Clinical Trial Results

Application of SpaceOAR hydrogel results in lower long-term rectal injury and higher patient quality of life scores

Augmenix, SpaceOAR System, prostate cancer, three-year clinical data results, ASTRO 2016

October 27, 2016 — Augmenix Inc. announced the three-year results from the SpaceOAR System Prostate Cancer US Pivotal Clinical Trial in September at the 2016 annual meeting of the American Society for Radiation Oncology (ASTRO).

The study results, presented by Daniel Hamstra, M.D., Ph.D., a radiation oncologist at Texas Oncology in Irving, Texas, demonstrated significantly lower rectal toxicity and higher patient quality of life (QOL) scores when the SpaceOAR System was applied prior to radiotherapy as compared to the trial control patients.

The leading side effects of prostate cancer radiotherapy are collectively known as “rectal toxicity” (diarrhea, rectal bleeding, urgency, pain, etc.), which results from unintended radiation injury to the rectum (the Organ At Risk, OAR). These complications can last for years, significantly impacting QOL. The SpaceOAR System was developed to push the rectum away from the high dose region during treatment, and then to be completely absorbed by the body after radiotherapy is complete.

The prospective, randomized, multi-center, patient-blinded clinical trial evaluated rectal and urinary toxicity and QOL impact on prostate radiotherapy patients treated either with SpaceOAR hydrogel, or with no hydrogel (controls). Previously published initial study results demonstrated spacer safety, and a significant 74 percent reduction in the volume of rectum receiving 70 Gy radiation at 15 months.

Following radiotherapy through three years, no SpaceOAR patients (0 percent) experienced grade 2 or worse late rectal toxicity, compared to 5.7 percent in the control patients (p=0.012). Additionally, at three years the average SpaceOAR patient bowel QOL was slightly better than before radiotherapy (+0.48 points), while the control patients QOL had significantly declined (-5.3 points, p=0.05). The percent of men with significant 10+ declines in bowel QOL at three years was 20.5 percent and 5.4 percent in the control and SpaceOAR groups (p=0.02), respectively.

Unexpectedly, the SpaceOAR patients also showed benefits in urinary complications and QOL, relative to controls. In the three years after radiotherapy, grade 1 urinary incontinence was experienced in 19.6 percent and 4.3 percent of the control and SpaceOAR patients, respectively (p=0.003). Additionally, like bowel QOL, at three years the average SpaceOAR patient urinary QOL was slightly better than before radiotherapy (+0.6 points), while the control patient QOL had declined (-3.3 points, p=0.05).

“The low level of rectum radiation dose seen in the men who received the spacer in this trial is unprecedented, and it is great to see that the spacer rectum protection is resulting in long-term patient benefits,” said Hamstra. “The idea that three years after treatment patients can be having the same bowel and urinary QOL is wonderful. Essentially patients can complete their treatment and be confident that life can return to normal.”

Using a minimally invasive procedure, the SpaceOAR System is injected as a liquid into the space between the prostate and rectum, where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy, and then liquefies and is completely absorbed.

The SpaceOAR System is U.S. Food and Drug Administration (FDA)-cleared, CE marked and is also approved in Australia and Canada.

For more information:

Related Content

Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Life Image and Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...